|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer.
|
20473859 |
2011 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Herein we aimed to uncover the potential oncogenic role of PRMT6 in prostate carcinogenesis.
|
27323813 |
2016 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that PELP1 oncogenic functions involve alternative splicing leading to the activation of unique pathways that support tumor progression and that the PELP1-PRMT6 axis may be a potential target for breast cancer therapy.
|
24447537 |
2014 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that dysregulation of PRMT6-dependent transcription and alternative splicing may be involved in breast cancer pathophysiology and the molecular consequences identifying a unique and informative biomarker profile.
|
22673335 |
2012 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we investigate the molecular mechanism by which protein arginine methyltransferase 6 (PRMT6) exerts anti-invasiveness effect against breast cancer cells and prostate cancer cells.
|
23380452 |
2013 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PRMT6 knock-down (KD) results in a p21 derepression in breast cancer cells, which is p53-independent, and leads to cell cycle arrest, cellular senescence and reduced growth in soft agar assays and in severe combined immunodeficiency (SCID) mice for all the cancer lines examined.
|
22987071 |
2012 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of tumor suppressor PCDH7 in the PRMT6-KO GC cells elevated cell migration and invasion.
|
30508037 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Stable PRMT6 knockdown in PC-3 cells attenuated malignant phenotype, increasing apoptosis and decreasing cell viability, migration and invasion.
|
27323813 |
2016 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Significant association of PRMT6 hypomethylation with colorectal cancer.
|
29927001 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Silencing of PRMT6 promoted the tumor-initiating, metastasis, and therapy resistance potential of HCC cell lines and patient-derived organoids.
|
30332648 |
2018 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Collectively, our data suggest that PELP1 oncogenic functions involve alternative splicing leading to the activation of unique pathways that support tumor progression and that the PELP1-PRMT6 axis may be a potential target for breast cancer therapy.
|
24447537 |
2014 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our work describes a critical repressive function for PRMT6 in maintenance of HCC cells by regulating RAS binding and MEK/ERK signaling via methylation of CRAF on arginine 100.
|
30332648 |
2018 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, we showed as a proof-of-concept the therapeutic potential of using 2-deoxyglucose (2DG), a glycolysis inhibitor, to reverse tumorigenicity and sorafenib resistance mediated by PRMT6 deficiency in HCC.
|
31469916 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.020 |
Biomarker
|
disease |
BEFREE |
Although the cellular role of PRMT6 is not well understood, it has been implicated in human immunodeficiency virus pathogenesis, DNA repair, and transcriptional regulation.
|
19509293 |
2009 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
Significant association of PRMT6 hypomethylation with colorectal cancer.
|
29927001 |
2018 |
|
Colonic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Levels of DNA methyltransferase 1 (DNMT1) and protein arginine methyltransferase 6 (PRMT6) were increased in colon tumors from Ppara<sup>ΔIE</sup> mice, compared with colon tumors from control mice.
|
31154022 |
2019 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
IMPLICATIONS: This is the first study to demonstrate an <i>in vivo</i> role for PRMT6 in lung tumor progression via the alternate activation of TAMs.
|
31619507 |
2020 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
By analyzing biological functions of PRMT6 in GC cell lines by lentivirus-based systems, PRMT6 overexpression enhanced global H3R2me2as and invasiveness in vitro, while PRMT6 knockout (PRMT6-KO) suppressed these effects and tumorigenicity in vivo.
|
30508037 |
2019 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
The abundance of hepatic PRMT6 was increased in mouse models of obesity and insulin resistance, and adenovirus-mediated depletion of PRMT6 restored euglycemia in these mice.
|
24570487 |
2014 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To identify in a nonbiased manner genes regulated by PRMT6 expression, we performed a microarray analysis on U2OS osteosarcoma cells transfected with control and PRMT6 small interfering RNAs.
|
19509293 |
2009 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
To interrogate the <i>in vivo</i> functions of PRMT6 in lung cancer, we developed a tamoxifen-inducible lung-targeted PRMT6 gain-of-function mouse model, which mimics PRMT6 amplification events in human lung tumors.
|
31619507 |
2020 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
PRMT6 plays an oncogenic role in PCa and predicts for more clinically aggressive disease, constituting a potential target for patients with CRPC.
|
27323813 |
2016 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
To identify in a nonbiased manner genes regulated by PRMT6 expression, we performed a microarray analysis on U2OS osteosarcoma cells transfected with control and PRMT6 small interfering RNAs.
|
19509293 |
2009 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
PRMT6 plays an oncogenic role in PCa and predicts for more clinically aggressive disease, constituting a potential target for patients with CRPC.
|
27323813 |
2016 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
To interrogate the <i>in vivo</i> functions of PRMT6 in lung cancer, we developed a tamoxifen-inducible lung-targeted PRMT6 gain-of-function mouse model, which mimics PRMT6 amplification events in human lung tumors.
|
31619507 |
2020 |